Key Takeaways
-
DSO equity can represent a large share of your proceeds, so you benefit from evaluating the buyer’s financial stability before signing an LOI.
-
Standard financial formulas often miss key risks in dental M&A because of recapitalization cycles, equity structures, and post-close performance risk.
-
Owners can request 3 years of audited financials, normalize earnings, and calculate metrics like DSO, DSCR, and current ratio to spot concerns.
-
Reviewing AR aging, bad-debt write-offs, and liquidity ratios can help you sort DSOs into stable, caution, or high-risk categories.
-
Before accepting DSO equity, you may want to work with McLerran & Associates to underwrite the buyer like an investment and protect long-term proceeds.
The Problem: Why Generic DSO Formulas Fall Short in Dental M&A
Standard financial analysis often treats all buyers the same, while dental M&A behaves differently. Three structural realities can be some of the main factors that make DSO evaluation very different from evaluating a private buyer.
First, recapitalization cycles matter. A recapitalization, where a DSO sells a majority stake to a new private equity sponsor while keeping existing debt and equity holders in place, is not a distant possibility. According to the TUSK Practice Sales Q2 2026 Dental Market Report, a substantial percentage of surveyed DSOs anticipate recapitalization within 12 to 36 months. The seller’s rolled-over equity participates in that event, which can increase or decrease value.
Second, equity structure shapes your outcome. DSO equity can be held at the joint-venture (JV) level, which ties value to the individual practice’s performance, or at the holding-company (HoldCo) level, which is a stake in the entire platform. Each structure carries different liquidity, upside, and risk profiles. JV, HoldCo, and hybrid equity structures now function as strategic levers in DSO transactions, so you benefit from knowing exactly what you own before signing.
Third, post-close performance risk can be significant. Minority equity holders in privately held DSOs often have limited access to financial information and little influence over restructuring decisions. That reality exposes rolled-over equity to meaningful value changes when ownership or capital structure shifts. Generic formulas usually do not account for these dynamics.
Step 1: Gather and Normalize Financial Statements
Action: Request 3 years of audited or reviewed financial statements for the DSO at both the platform (holding-company) and location levels. Then adjust the numbers for non-recurring items, management fees, and intercompany charges.
Required data: Income statements, balance sheets, cash-flow statements, and any quality-of-earnings (QoE) reports the DSO has commissioned. A QoE is an independent analysis that checks whether reported earnings are real, recurring, and sustainable.
Decision point: If the DSO cannot or will not provide location-level financials, that opacity can be a red flag. DSO location-level EBITDA, tracked before corporate overhead allocation, serves as the closest measure of true operating health and should be available to any serious equity partner.
Normalizing financials is technical work. A sell-side advisor with CPA-led analytical capability can request, interpret, and challenge this data on your behalf.
Step 2: Calculate and Trend the DSO Metric Over 12–36 Months
Action: Calculate days sales outstanding (DSO) for each of the past 12 to 36 months. DSO is the average number of days it takes the organization to collect revenue after a service is performed. The formula is total accounts receivable divided by average daily collections.
Required data: Monthly accounts receivable (AR) aging reports and monthly collection totals at the platform and location levels.
Decision point: A trend in DSO usually tells you more than a single figure. Top-performing organizations with centralized billing can collect quickly, while higher values can signal revenue-cycle stress that deserves deeper review. A rising trend, even within an acceptable range, calls for an explanation.
Step 3: Compare DSO Metrics to Dental Benchmarks and Payer Mix
Action: Compare the DSO’s DSO figure and AR aging distribution to current dental-industry benchmarks, segmented by organization type.
Required data: AR aging by bucket (0–30, 31–60, 61–90, 90+ days) and payer-mix breakdown (insurance vs. patient-pay vs. Medicaid).
Decision point: Payer mix can be one of the main factors that shapes what a “normal” DSO looks like. DSO should be compared to industry peers and stated payment terms rather than a universal 30-day target. A 55-day DSO may be poor for retail but reasonable for sectors with complex billing such as healthcare. A DSO with heavy Medicaid concentration will naturally run higher DSO than a fee-for-service platform. Practices with significant Medicaid payer concentration in states facing uncertain legislative direction are being evaluated conservatively by DSO buyers, and that same risk can apply to sellers evaluating DSO equity.
Step 4: Stress-Test AR, Denials, and Write-Offs for Red Flags
Action: Review the AR aging report for concentration in older buckets, sudden bad-debt spikes, and write-off patterns that do not match stated policy changes.
Required data: Twenty-four to 36 months of AR aging by bucket, bad-debt write-off schedules, and denial-rate reports by payer and location.
Decision point: Specific thresholds to flag include:
-
90+ day AR exceeding 10% of total AR, where collectibility can fall sharply
-
Bad-debt write-offs above 2% of production, which can indicate breakdowns in front-desk collections or patient communication
-
Claim denial rates above 5% for a payer or location, which can point to documentation, coding, or eligibility verification issues
-
Stale insurance balances on routine procedures aging past 45 days and sudden write-off spikes without policy changes, which can indicate that reported collections are overstated
Each of these thresholds represents a different point of failure in the revenue cycle, from claim submission to aging receivables to final write-off. When several thresholds are breached at the same time, they can compound and suggest that reported EBITDA overstates actual cash generation, because revenue is being recognized before it is collectible.
Step 5: Review Liquidity and Debt Coverage Ratios Together
Action: Calculate three ratios that measure the DSO’s ability to meet its obligations: the current ratio, the debt service coverage ratio (DSCR), and the cash-conversion cycle.
Required data: Balance sheet details for current assets and current liabilities, net operating income, total annual debt service (principal plus interest payments), and monthly cash-flow statements.
Decision point:
-
Current ratio (current assets ÷ current liabilities): A ratio below 1.0 often concerns lenders because current liabilities exceed available current assets.
-
DSCR (net operating income ÷ total debt service): A DSCR of 1.25 or higher usually signals a comfortable buffer to service debt. A DSO-level DSCR below 1.0 means the platform cannot cover its debt from operations alone.
-
Cash-conversion cycle: This is the time between delivering a service and collecting cash. Regulations in states such as New Jersey require clean insurance claims, including dental, to be paid within 30 days if submitted electronically or 40 days if submitted on paper. A denied or resubmitted claim can extend the timeline to 60 to 90 days or longer. A structurally long cash-conversion cycle may hide working-capital stress.
Step 6: Use a Sell-Side Advisor to Request and Interpret Buyer Data
Action: Engage a sell-side advisor to formally request, organize, and interpret the financial data above, and to benchmark it against comparable DSO transactions.
Required data: Everything gathered in Steps 1 through 5, plus the DSO’s capitalization table, debt maturity schedule, and any existing quality-of-earnings reports.
Decision point: An unrepresented seller who requests this data directly from a DSO often starts at a structural disadvantage. Dentists selling to DSOs now face buyer demands for larger rollover equity positions, earn-out provisions, and more extensive financial documentation and performance guarantees, so the information flow usually runs toward the buyer. A sell-side advisor can balance that table, shape the narrative around your EBITDA, and help ensure the data you receive is interpreted with your interests in mind.
Stable vs. Caution vs. High-Risk Metrics in a Dental Context
The table below summarizes the thresholds discussed in the earlier steps. It shows at a glance which metric values often indicate stable operations, which call for caution, and which can signal higher risk to your rolled-over equity.
|
Metric |
Stable |
Caution |
High-Risk |
|---|---|---|---|
|
Days Sales Outstanding (DSO) |
Strong performance (top-performing DSO orgs with centralized billing) |
Moderate range |
Elevated range that warrants deeper diligence |
|
AR Aged 90+ Days (% of total AR) |
Under 10% |
10–15% |
Above 15% (collectibility often falls sharply) |
|
DSCR (Debt Service Coverage Ratio) |
1.25x or higher |
1.0x–1.24x (limited buffer) |
Below 1.0x (operations cannot cover debt) |
|
Current Ratio (Current Assets ÷ Current Liabilities) |
Healthy range (above 1.0x) |
Near 1.0x (limited buffer) |
Below 1.0x (current liabilities exceed assets) |
|
Bad-Debt Write-Offs (% of production) |
Under 1% (DSO-affiliated benchmark) |
1–2% (group practice range) |
Above 2% (front-desk or billing breakdown) |
|
Location-Level EBITDA (% of net collections) |
20–35% (high-performing DSO target) |
15–19% (below benchmark) |
Under 15% (operational discipline concern) |
Good-DSO vs. Bad-DSO Vignette
Two anonymized scenarios drawn from McLerran & Associates’ work can illustrate how these metrics play out in practice.
Scenario A: Stable platform. A multi-state DSO presents 3 years of audited financials showing DSO trending from 32 days to 27 days, 90+ day AR consistently below 8% of total AR, a platform DSCR of 1.35x, and bad-debt write-offs under 1% of production. Location-level EBITDA averages 24% of net collections before corporate overhead. The capitalization table shows a well-capitalized private equity sponsor with a clear exit horizon. The checklist produces no material red flags. The seller then negotiates equity structure and earnout terms from a position of informed confidence.
Scenario B: Distressed platform. A DSO with an attractive headline multiple presents financials showing DSO rising from 38 days to 61 days over 24 months, 90+ day AR at 19% of total AR, a platform DSCR of 0.92x, and bad-debt write-offs at 3.1% of production. The debt maturity schedule shows a large balloon payment due within 18 months. PE-backed DSOs that loaded up on variable-rate or short-term debt during the low-rate 2018–2022 period now face a different cost-of-capital environment, where revenue growth has not kept pace with rising debt service. Without the checklist, a seller might have accepted 35% of the deal in HoldCo equity that later becomes impaired in a lender-driven restructuring before the anticipated recapitalization occurs.
The gap between these two outcomes reflects diligence and structure, not luck.
How McLerran & Associates Equips Owners with Diligence-Grade Tools
McLerran & Associates is a dental-specific, sell-side-only advisory firm. Every engagement begins with a CPA-led EBITDA analysis, which is diligence-grade work done before the practice goes to market so the numbers hold up when buyers scrutinize them.
For owners evaluating DSO paths, that foundation extends into multi-year, multi-structure financial forecasting. McLerran models what each deal structure, including JV equity, HoldCo equity, hybrid structures, and earnouts, can net the owner over 3-, 5-, 7-, and 10-year horizons, conservatively assuming one recapitalization in years five to seven. That modeling turns a DSO’s financial stability checklist into a practical decision about what your equity can look like under each scenario.
The firm also vets buyers before they reach the table. McLerran runs a structured, auction-like bid process, typically 45 to 60 days and generating around 10 offers, among a pre-qualified pool of well-backed buyers. Poorly run or undercapitalized DSOs are excluded. Owners see the real market, not a single offer from a single buyer with no competitive tension.
The firm’s track record includes approximately 2,000 successful practice sales, roughly $2 billion in closed transaction volume, and a transaction rate of about 85 to 90%, compared to an industry norm closer to 35 to 40%.
Frequently Asked Questions
When in the process should I start evaluating a DSO’s financial stability?
Evaluation usually works best before you sign a letter of intent. The LOI is the binding term sheet that locks in deal structure, including how much of your proceeds will be paid in equity. Once signed, your leverage to renegotiate those terms often drops. Financial stability diligence can guide your choice of which DSOs to engage seriously rather than serving as a post-LOI formality.
What financial data can I actually request from a DSO before signing?
Most sellers can request more than they expect. A well-represented seller can ask for 3 years of audited or reviewed financial statements at both the platform and location levels, AR aging reports, debt maturity schedules, and any existing quality-of-earnings reports. DSOs that refuse to provide location-level financials or debt schedules to a serious prospective equity partner may be signaling issues that deserve attention. A sell-side advisor can frame these requests professionally and interpret the responses.
What is the difference between JV equity and HoldCo equity, and why does it matter for financial stability?
JV (joint-venture) equity is a stake in the individual practice or a small cluster of practices. It typically generates distributions, which are regular cash payments from the practice’s earnings, so it can have a higher floor but a lower ceiling. HoldCo (holding-company) equity is a stake in the entire DSO platform. It generally pays no distributions, but it can multiply if the DSO achieves a successful private equity exit at a higher multiple than what was paid to build the platform. The financial stability of the DSO can matter more for HoldCo equity holders, because their entire stake is exposed to platform-level leverage, restructuring risk, and exit timing, which minority holders do not control.
What are the clearest signs that a DSO’s financial stability poses a risk to my rolled-over equity?
Some of the most actionable red flags include a DSO trend that rises consistently over 24 to 36 months, 90-plus day AR moving into the mid-teens or higher as a share of total AR, a debt service coverage ratio below 1.0x, and bad-debt write-offs above 2% of production. A large debt maturity event within 18 to 24 months with no clear refinancing plan and a capitalization table showing the private equity sponsor is well past its typical hold period with no announced exit process can also raise concern. Any one of these can justify deeper diligence, while several together may suggest structural financial stress.
When should I walk away from a DSO deal entirely?
Walking away can make sense when the financial stability checklist produces multiple high-risk signals and the DSO cannot or will not provide credible explanations supported by data. It can also make sense when the equity structure concentrates too much of your proceeds in HoldCo equity tied to a platform with a deteriorating DSCR, a rising DSO trend, and near-term debt maturity. In some cases, the better path is not to walk away but to negotiate a higher cash-at-close percentage that reduces your equity exposure to a level that fits the risk. A sell-side advisor can model both paths and help you weigh which outcome aligns with your goals.
Next Step: Underwrite Your Buyer Like an Investment
You built your practice over years or decades. The equity component of a DSO deal can represent a substantial share of your total proceeds, and its value depends on the financial health of a platform you will have limited ability to influence after closing. The six-step checklist above offers a starting point for evaluating that risk with the same rigor a DSO applies when it evaluates your practice.
McLerran & Associates has guided owners through thousands of practice sales and evaluated more than 10,000 practices. The firm’s CPA-led EBITDA analysis, multi-structure financial forecasting, and vetted buyer pool can help convert this checklist from a framework into a defensible decision.
Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your goals, and how to underwrite any buyer like the investment it is. Call (512) 900-7989 or email info@dentaltransitions.com.
